Champignon Brands Inc., a wellness company specializing in the formulation and distribution of a suite of medicinal mushroom-infused products, is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “SHRM”.
Additional Information:
Video Transcript:
I’m Nadika Viswakula for Investmentpitch Media
Champignon Brands Inc., a wellness company specializing in the formulation and distribution of a suite of medicinal mushroom-infused products, is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “SHRM”.
Gareth Birdsall, CEO, stated: “We are dedicated to transforming the health and wellness industry via the infusion of our proprietary blend of medicinal mushrooms. We’ve been assembling a dedicated roster of mycologists and health and wellness professionals to formulate several distinctive lines of premium fungi extracts. The overall product portfolio is tailored for conscious consumers looking to support mental health and bolster cognitive performance through medicinal mushroom based products. We believe that we are only scratching the surface when it comes to unlocking the benefits hidden in medicinal mushrooms.”
To date, the company has focused on the distribution of its flagship brand Vitality Superteas line of products.
Champignon Brands and Drip Coffee Social Ltd. have entered into a R&D and Product Formulation partnership whereby Drip will infuse Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.
With dedicated global fulfillment infrastructure in place, the company is positioned to capitalize on the burgeoning craft mushroom market, affording current and prospective customers the ability to procure a selection of mushroom-infused products.
Champignon is proceeding with the formation of a special advisory committee to evaluate the potential positive effects its medicinal mushroom formulations could have on individuals suffering from mental health disorders such as depression, PTSD as well as substance and alcohol use disorders.
The Company will appoint advisory board members who are qualified and experienced in areas such as medicine, psychology, mycology, and pharmacology to assist with this research initiative.
The company raised gross proceeds of approximately $2,837,000 from the sale of approximately 18.9 million shares priced at $0.15 per share, with PI Financial acting as agent for the IPO.
The shares are trading at $0.26.
For more information, please visit the company’s website www.champignonbrands.com, contact Gareth Birdsall, CEO, at 778-809-6664 or by email at info@champignonbrands.com.
I’m Nadika Viswakula for Investmentpitch Media
